Table 2 Pharmacokinetic parameters of EGT710 following single intravenous or oral dosing in mouse, rat and dog

From: Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor

 

Oral PK parameters

Intravenous PK parameters

Species

Dose (mg/kg)

Cmax (ng/mL)

Tmax mean (h)

AUCinf (µg x h/mL)

F (%)

Dose (mg/kg)

Vss (L/kg)

CL (mL/min/kg)

T1/2 (h)

AUCinf (µg x h/mL)

Mouse

30

5443

1.0

36.38

39.3

1.0

1.30

5.51

2.64

3.25

Rat

10a

2422

2.5

34.61

>100

1.0

2.01

4.86

5.67

3.43

 

100a

14795

1.0

421.63

>100

     

Dog

10

2066

2.3

27.33

84.3

1.0

3.67

5.18

8.38

3.23

  1. Cmax maximum concentration achieved; Tmax time of peak concentration, AUCinf area under the curve from time 0 to infinity, F absolute oral bioavailability, Vss volume of distribution at steady state, CL total systemic clearance, T1/2 terminal elimination half-life.
  2. adata presented in ref. 7 was converted to ng/ml using the molecular weight of 383.3 g/mol.
Back to article page